Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Smith & NephewCHIX:SNL -2.50%85 EV-to-EBITDA is 10.37 as of Aug. 03, 2026, which is 27% below its 10-year median of 14.12. GuruFocus rates CHIX:SNL with a GF Score™ of 85/100 and a GF Value™ of £11.90 (Fairly Valued). The stock has 3 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Smith & Nephew ranks better than 65.23% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Smith & Nephew's enterprise value is £11,795 Mil.
Smith & Nephew's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £1,137 Mil. Therefore, Smith & Nephew's EV-to-EBITDA for today is 10.37.
The historical rank and industry rank for Smith & Nephew's EV-to-EBITDA or its related term are showing as below:
CHIX:SNl'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.27 Med: 14.12 Max: 24.73
Current: 10.14
During the past 13 years, the highest EV-to-EBITDA of Smith & Nephew was 24.73. The lowest was 9.27. And the median was 14.12.
CHIX:SNl's EV-to-EBITDA is ranked better than 65.23% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.37
vs CHIX:SNl: 10.14
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Smith & Nephew (CHIX:SNl) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Smith & Nephew's PE Ratio (TTM) for today is calculated as:
Smith & Nephew's share price for today is £11.5925.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Smith & Nephew's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £0.531.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Smith & Nephew's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:SNL vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Smith & Nephew's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Smith & Nephew EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Smith & Nephew's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Smith & Nephew's EV-to-EBITDA falls into.
Smith & Nephew's current Enterprise Value is £11,795 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Smith & Nephew's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £1,137 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Smith & Nephew (CHIX:SNL) has a EV-to-EBITDA of 10.37 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Smith & Nephew. This is 27% below median its historical median of 14.12. Over the past decade, Smith & Nephew's EV-to-EBITDA has ranged from 9.27 to 24.73. According to the industry distribution chart, Smith & Nephew ranks #178 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 34.8%.
Is Smith & Nephew's EV-to-EBITDA too high?
Smith & Nephew's current EV-to-EBITDA of 10.37 is 27% below median its 10-year median of 14.12. Over the past 10 years, this metric has ranged from a low of 9.27 to a high of 24.73. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.37. Smith & Nephew's value of 10.37 is 27.8% below this industry median. Based on the distribution chart, Smith & Nephew ranks #178 out of 512 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Smith & Nephew has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Smith & Nephew's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Smith & Nephew ranks #178 out of 512 companies for EV-to-EBITDA. This puts Smith & Nephew in the upper half of its industry. The industry median EV-to-EBITDA is 14.37. Smith & Nephew's value of 10.37 is 27.8% below this benchmark. Historically, Smith & Nephew's own EV-to-EBITDA has ranged from 9.27 to 24.73 over the past decade. While the company's 10-year median is 14.12 vs. the industry median of 14.37, Smith & Nephew has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.37, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Smith & Nephew's current EV-to-EBITDA of 10.37 is 27.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Smith & Nephew. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Smith & Nephew's current EV-to-EBITDA is 10.37, which is 27% below median its own 10-year median of 14.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Smith & Nephew stock overvalued right now?
Based on GuruFocus' analysis, Smith & Nephew (CHIX:SNL) is currently considered Fairly Valued. The stock's GF Value™ is £11.90, compared to a current price of £11.59 — trading 2.6% below its estimated fair value. The current EV-to-EBITDA is 10.37, which is 27% below median its 10-year median of 14.12 and 27.8% below the Medical Devices & Instruments industry median of 14.37. Smith & Nephew's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Smith & Nephew (CHIX:SNL), the current EV-to-EBITDA is 10.37 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Smith & Nephew (CHIX:SNL) Overvalued in 2026?
Based on GuruFocus' analysis, Smith & Nephew stock appears to be undervalued.
The current stock price of £11.59 is trading 2.6% below its estimated GF Value™ of £11.90.
GuruFocus considers Smith & Nephew to be Fairly Valued.
Key valuation signals for CHIX:SNL:
EV-to-EBITDA: 10.37 (27% below median its 10-year median of 14.12)
GF Value™: £11.90 vs. price of £11.59 (2.6% below fair value)
Industry Position: 27.8% below the Medical Devices & Instruments median (#178 of 512)
No single metric tells the full story. See the CHIX:SNL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
85GF Score
Get the complete analysis for CHIX:SNL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SNL has been successfully added to your 
